How do recent RxPonder results affect your adjuvant therapy choice for premenopausal women with HR+/HER2 negative breast cancer with 1-3 positive LNs?

In the RxPONDER clinical trial, all premenopausal patients with HR+ HER2-negative breast cancer with 1-3 positive LNs had a benefit from adjuvant chemotherapy regardless of their Oncotype DX RS. Therefore, there would not be a need to send for an Oncotype or Mammaprint. This management would not change in patients who received SLNB vs. ALND. There are many questions that cannot be directly answered from the results of this study such as using ovarian suppression instead of chemotherapy or what s...